DUPIXENT
DUPIXENT (dupilumab) is a biologic therapy co-developed by Regeneron and Sanofi that blocks the interleukin-4 receptor alpha (IL-4Rα), shutting down the IL-4 and IL-13 signaling pathways that drive type 2 inflammation — the immune overreaction underlying atopic dermatitis, asthma, chronic sinusitis, and other allergic conditions. It is given by subcutaneous injection every two weeks and is among the most commercially successful biologic drugs of the past decade, approved across atopic dermatitis, asthma, CRS with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, and alopecia areata. Regeneron continues to expand its approved age range and indications in ongoing trials.
Upcoming catalysts
Programs
Atopic Dermatitis
Atopic dermatitis is the most common inflammatory skin disease, affecting up to 20% of children in high-income countries through chronic itch and skin barrier dysfunction driven by type 2 immune overactivation. DUPIXENT is already the dominant biologic in AD, approved down to age 6 months in some markets; this specific program extends the US label to cover patients aged 6 months to 5 years, measuring EASI-75 response and pruritus NRS reduction versus placebo in the youngest pediatric segment.